Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Other Operating Expenses (2018 - 2019)

Serina Therapeutics (SER) has disclosed Other Operating Expenses for 2 consecutive years, with -$6.9 million as the latest value for Q1 2019.

  • Quarterly Other Operating Expenses changed N/A to -$6.9 million in Q1 2019 from the year-ago period, while the trailing twelve-month figure was -$6.9 million through Dec 2019, up 43.28% year-over-year, with the annual reading at $73000.0 for FY2023, N/A changed from the prior year.
  • Other Operating Expenses hit -$6.9 million in Q1 2019 for Serina Therapeutics, up from -$7.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of -$5.2 million in Q3 2018 to a low of -$7.0 million in Q4 2018.